Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
Author:
Open Access
- 18 December 2009
- journal article
- clinical trial
- Published by Springer Nature in BMC Neurology
- Vol. 9 (1) , 62
Abstract
Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly binding to the type-2 vesicular monoamine transporter. A previous double blind study in Huntington disease (HD) demonstrated that TBZ effectively suppressed chorea, with a favorable short-term safety profile (Neurology 2006;66:366-372). The objective of this study was to assess the long-term safety and effectiveness of TBZ for chorea in HD.Keywords
This publication has 31 references indexed in Scilit:
- The Long-term Effect of Tetrabenazine in the Management of Huntington DiseaseClinical Neuropharmacology, 2008
- The current clinical management of Huntington's diseaseMovement Disorders, 2008
- Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's DiseaseThe Journal of Neuroscience, 2007
- Short‐term effects of tetrabenazine on chorea associated with Huntington's diseaseMovement Disorders, 2007
- Is History of Depression a Contraindication to Treatment With Tetrabenazine?Clinical Neuropharmacology, 2006
- Critical Periods of Suicide Risk in Huntington’s DiseaseAmerican Journal of Psychiatry, 2005
- Tourettism associated with Huntington's diseaseMovement Disorders, 1995
- Suicide risk in Huntington's disease.Journal of Medical Genetics, 1993
- Suicide and attempted suicide in Huntington disease: Implications for preclinical testing of persons at riskAmerican Journal of Medical Genetics, 1986
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960